Healthcare provider profile · identity verified

Susan E Pelini, MD

Internal Medicine · HOUSTON, TX · NPI 1154370914

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	401	113
Lisinopril	Lisinopril	217	56
Amlodipine Besylate	Amlodipine Besylate	204	69
Losartan Potassium	Losartan Potassium	143	42
Carvedilol	Carvedilol	132	39
Gabapentin	Gabapentin	129	42
Hydrochlorothiazide	Hydrochlorothiazide	119	34
Levothyroxine Sodium	Levothyroxine Sodium	119	38
Nifedipine Er	Nifedipine	113	34
Metformin Hcl	Metformin Hcl	100	33
Pantoprazole Sodium	Pantoprazole Sodium	94	30
Metoprolol Succinate	Metoprolol Succinate	89	30
Fluticasone Propionate	Fluticasone Propionate	84	36
Omeprazole	Omeprazole	77	24
Simvastatin	Simvastatin	65	18
Furosemide	Furosemide	62	23
Tamsulosin Hcl	Tamsulosin Hcl	61	17
Rosuvastatin Calcium	Rosuvastatin Calcium	58	20
Eliquis	Apixaban	55	22
Levetiracetam	Levetiracetam	51	11
Escitalopram Oxalate	Escitalopram Oxalate	49	14
Zolpidem Tartrate	Zolpidem Tartrate	47	suppressed
Duloxetine Hcl	Duloxetine Hcl	46	15
Trazodone Hcl	Trazodone Hcl	44	13
Ozempic	Semaglutide	41	suppressed
Alendronate Sodium	Alendronate Sodium	39	13
Metoprolol Tartrate	Metoprolol Tartrate	38	16
Diclofenac Sodium	Diclofenac Sodium	36	18
Sertraline Hcl	Sertraline Hcl	36	12
Jardiance	Empagliflozin	35	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	34	19
Metformin Hcl Er	Metformin Hcl	34	12
Tramadol Hcl	Tramadol Hcl	34	suppressed
Famotidine	Famotidine	32	suppressed
Baclofen	Baclofen	31	11
Synthroid	Levothyroxine Sodium	31	suppressed
Allopurinol	Allopurinol	29	11
Clopidogrel	Clopidogrel Bisulfate	29	suppressed
Mirtazapine	Mirtazapine	29	suppressed
Potassium Chloride	Potassium Chloride	29	14
Estradiol	Estradiol	27	suppressed
Montelukast Sodium	Montelukast Sodium	27	suppressed
Propranolol Hcl Er	Propranolol Hcl	26	suppressed
Citalopram Hbr	Citalopram Hydrobromide	24	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	21	suppressed
Tizanidine Hcl	Tizanidine Hcl	21	suppressed
Hydralazine Hcl	Hydralazine Hcl	20	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	20	suppressed
Valacyclovir	Valacyclovir Hcl	20	suppressed
Bupropion Xl	Bupropion Hcl	19	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	19	suppressed
Paroxetine Hcl	Paroxetine Hcl	19	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	18	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	18	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	18	suppressed
Propranolol Hcl	Propranolol Hcl	18	suppressed
Spironolactone	Spironolactone	18	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	18	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	18	suppressed
Xarelto	Rivaroxaban	18	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	16	suppressed
Pravastatin Sodium	Pravastatin Sodium	16	suppressed
Atenolol	Atenolol	15	suppressed
Hydrocortisone	Hydrocortisone	15	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	14	suppressed
Ibuprofen	Ibuprofen	14	suppressed
Lorazepam	Lorazepam	14	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	14	suppressed
Chlorpromazine Hcl	Chlorpromazine Hcl	13	suppressed
Entresto	Sacubitril/Valsartan	13	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	13	suppressed
Celecoxib	Celecoxib	12	suppressed
Doxepin Hcl	Doxepin Hcl	12	suppressed
Warfarin Sodium	Warfarin Sodium	12	suppressed
Clonazepam	Clonazepam	11	suppressed
Clotrimazole	Clotrimazole	11	suppressed
Ketoconazole	Ketoconazole	11	suppressed
Prednisone	Prednisone	11	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	11	suppressed
Valsartan	Valsartan	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error